13 results about "Sodium iodate" patented technology

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

The invention discloses application of cnidium lactone in preparation of a medicine for treating AMD or corneal injury, and belongs to the field of biological medicine. It is found for the first time that the cnidium lactone can inhibit sodium iodate induced retinal pigment epithelial cell injury, and it is also found for the first time that the cnidium lactone can promote injured cornea repair; based on the discovery, the invention respectively provides application of cnidium lactone in preparation of medicines for treating age-related macular degeneration and preparation of medicines for treating corneal injury. Experimental results show that cnidium lactone can remarkably reverse the retinal pigment epithelial cell degradation trend caused by age-related macular degeneration and can also remarkably promote corneal notch healing. The invention provides a new optional medicine for treating age-related macular degeneration and corneal injury, expands the application range of cnidium lactone, and has outstanding clinical practical value and wide application prospect.

The application belongs to the technical field of papermaking and textile, and provides a preparation method of colored paper for yarns. Carboxylated nanocellulose, dopamine hydrochloride, a catalytic oxidation system and an alkaline buffer are mixed to perform a polymerization reaction to obtain a polydopamine composite nanocellulose system; the polydopamine composite nanocellulose system, paper pulp, a dye and a dyeing assistant are mixed to perform dyeing and wet forming in sequence to obtain the colored paper for yarns; and the catalytic oxidation system comprises silver nitrate and sodium iodate. The application provides a green, safe and convenient preparation method for preparing yarn paper with high color fastness, high dyeing uniformity and high strength.

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

The invention provides a method for inducing a dry macular degeneration model by injecting sodium iodate into a vitreous cavity of a C57BL / 6J mouse, and belongs to the field of disease model construction. The dry macular degeneration mouse vitreous cavity model is established by regulating and controlling the administration dosage of sodium iodate injected into the vitreous cavity, and stable induction of dry macular degeneration is achieved. The method is simple to operate and high in repeatability, and the established model can successfully simulate pathological characteristics of human dry macular degeneration. The model can be used for screening and evaluating potential therapeutic drugs aiming at the dry macular degeneration, provides an experimental platform for researching pathogenesis of the dry macular degeneration, and provides a theoretical basis for developing a new therapeutic method.

The invention relates to a construction method and application of an animal model with retina geographic atrophy (GA) accompanied by choroidal neovascularization (CNV) symptoms. According to the method, sodium iodate is injected at multiple points in the subretinal space of cynomolgus monkeys, so that the retina has typical and clinically close retinopathy GA and CNV symptoms, and the blank of animal models for preclinical evaluation of multi-target drugs for treating GA and CNV at present is filled.

The invention belongs to the field of sodium-ion battery energy storage devices, and particularly relates to a preparation method of an asphalt-based hard carbon material and a sodium-ion battery. The method specifically comprises the following steps: S1, mixing asphalt, elemental iodine and sodium iodate, and reacting for 2-20 hours under 0.1-1 Mpa and irradiation of an ultraviolet lamp at 110-220 DEG C; s2, after the reaction is finished, cooling to 80-100 DEG C, and keeping the temperature for 1-5 hours to sublimate and recover the iodine; and S3, heating the iodinated asphalt to 1100-1450 DEG C, carbonizing for 2-6 hours, crushing and grading to obtain the asphalt-based hard carbon material. The problems that a traditional asphalt crosslinking method is high in energy consumption, and the electrochemical performance is affected by crosslinking agent residues are solved. Under the catalytic condition of sodium iodate, elemental iodine and liquid asphalt are subjected to an oxidation cross-linking reaction in a liquid interval, and efficient recovery is realized by utilizing the mild cross-linking characteristic and the easy sublimation characteristic of iodine.

The application discloses a purification method for producing iodine-131 by a reactor with a uranyl nitrate solution as nuclear fuel, and comprises the following steps: adding a reducing agent into a crude iodine-131 product solution to reduce sodium iodine-131 into iodine-131 element; distilling the iodine-131 element to obtain iodine-131 element vapor; and absorbing the iodine-131 element vapor by using an alkaline solution to obtain a sodium iodine-131 solution product. The purification method can effectively remove radioactive impurities in the iodine-131 extracted from the reactor with the uranyl nitrate solution as the nuclear fuel, and can obtain the sodium iodine-131 solution product meeting the medical requirements. The purification method for the iodine-131 isotope is simple, and can effectively remove the impurities in the iodine-131 isotope, so that the iodine-131 isotope meets the medical requirements, and the average recovery rate of iodine can reach more than 90%.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of a fenerenone intermediate 4-cyano-2-methoxybenzaldehyde. The method comprises the following steps: adding 3-methoxy-4-methylbenzonitrile into chlorobenzene, adding N, N-dimethylformamide dimethyl acetal while stirring, carrying out a heating reaction, after the reaction is finished, carrying out vacuum concentration to remove the chlorobenzene, adding an organic solvent and water, adding sodium periodate at a controlled temperature, after the heat preservation reaction is finished, carrying out centrifugal filtration to remove sodium iodate, and separating the filtrate to obtain the 3-methoxy-4-methylbenzonitrile. And concentrating and drying an organic phase, adding a saturated alkane solvent, and crystallizing to obtain the 4-cyano-2-methoxybenzaldehyde. The method has the advantages of simple synthetic route, convenience in operation, low cost, small amount of three wastes, environment friendliness, recyclable solvent and high product purity, and is more suitable for industrial mass production.

This invention relates to the field of disinfectant technology, and more particularly to a dairy cow teat disinfectant that promotes the repair of damaged epidermis, its preparation method, and its application. By weight, the dairy cow teat disinfectant that promotes the repair of damaged epidermis comprises the following raw materials: 0.2-2 parts iodine, 0.1-5 parts sodium iodide, 0.1-0.5 parts sodium iodate, 0.1-10 parts skin-repairing active ingredients, 1-10 parts surfactant, 0.05-0.5 parts thickener, 2-10 parts lubricant, 0.1-0.5 parts wetting agent, and 0.15-1 part pH adjuster, with the balance being water. A novel surfactant, alkyl glycoside, is selected. In the disinfectant system, alkyl glycoside can efficiently complex with iodine to form highly stable complexed iodine, extending the shelf life of the formulation. In addition, the cow teat disinfectant in this solution also contains skin repair ingredients. While maintaining a highly effective bactericidal effect, it can also promote the repair of skin damaged by bacterial infection, promote the healing of abrasions on the cow teat epidermis, and reduce the risk of infection by pathogens due to exposed teat epidermal wounds.

The application discloses application of a DKK1 inhibitor in preparation of a medicine for treating dry age-related macular degeneration. The application finds that DKK1 is obviously increased in expression in a sodium iodate (NaIO3)-induced dry AMD cell and animal model. In an in-vitro experiment, siRNA targeting DKK1 can protect the morphology of retinal pigment epithelial cells and reduce the mortality rate, and in an in-vivo experiment, shRNA targeting DKK1 can relieve patchy loss of retinal pigment epithelial cells and protect the retinal pigment epithelial cells. Therefore, the application provides a new treatment target and treatment strategy for dry AMD, and has important clinical application value.